We previously reported for the first time that NSDHL regulates breast cancer cell proliferation and migration abilities, anti-cancer drug sensitivity, and tumor growth and metastasis and that high NSDHL expression is associated with reduced relapse-free survival (RFS) in patients with ER + breast cancer [28]. The gene discussed is NSDHL; the disease is breast cancer.